SCHEMBL9965920

SCHEMBL9965920

CC(C)(C)OC(=O)N1C[C@@H]2C(C(=O)NNC(=O)CC(F)(F)F)[C@@H]2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.41
SSTR4 P31391 1/20 0.41
KMT2A Q03164 1/20 0.36
NAMPT P43490 1/20 0.36
TACR1 P25103 1/20 0.35
RORC P51449 1/20 0.35
PDE4B Q07343 1/20 0.34
LIPE Q05469 1/20 0.34
JAK3 P52333 1/20 0.34
KCNH2 Q12809 1/20 0.34
SCN5A Q14524 1/20 0.34
SCN9A Q15858 1/20 0.34
STS P08842 1/20 0.33
USP30 Q70CQ3 1/20 0.33
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PTPN2 P17706 1/20 0.33
PTPN1 P18031 1/20 0.33
PTPN6 P29350 1/20 0.33
DDB1 Q16531 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16182226 1.00 NR1H2 (0.41) NR1H2SSTR4KMT2ANAMPTTACR1
SCHEMBL12835644 1.00 NR1H2 (0.41) NR1H2SSTR4KMT2ANAMPTTACR1
SCHEMBL9933947 0.81
SCHEMBL9933948 0.81
SCHEMBL9965952 0.81 KMT2A (0.48) NR1H2SSTR4KMT2ASTSUSP2
SCHEMBL8284375 0.81 KMT2A (0.55) KMT2ASTSPTPN2PTPN1PTPN6
SCHEMBL20275276 0.76 SSTR4 (0.47) NR1H2SSTR4NAMPTPDE4BJAK3
SCHEMBL30241440 0.76 SSTR4 (0.48) NR1H2SSTR4NAMPTTACR1RORC
SCHEMBL25325266 0.75 NR1H2 (0.37) NR1H2NAMPTTACR1RORCPDE4B
SCHEMBL16182190 0.75 SSTR4 (0.46) NR1H2SSTR4NAMPTRORCPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NR1H2 122/4885SSTR4 462/4885KMT2A 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.